These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24444412)

  • 1. Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes.
    Jamaluddin JL; Huri HZ; Vethakkan SR; Mustafa N
    Pharmacogenomics; 2014 Feb; 15(2):235-49. PubMed ID: 24444412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice.
    Lu Y; Lu P; Wang Y; Fang X; Wu J; Wang X
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.
    Buteau J
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S73-7. PubMed ID: 18640589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.
    Furuta Y; Horiguchi M; Sugaru E; Ono-Kishino M; Otani M; Sakai M; Masui Y; Tsuchida A; Sato Y; Takubo K; Hochigai H; Kimura H; Nakahira H; Nakagawa T; Taiji M
    Diabetes Obes Metab; 2010 May; 12(5):421-30. PubMed ID: 20415690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.
    Mest HJ
    Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
    Juillerat-Jeanneret L
    J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
    Nauck MA
    Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
    Zhao Y; Yang L; Wang X; Zhou Z
    Diabetes Metab Res Rev; 2014 Nov; 30(8):646-53. PubMed ID: 24446278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding treatment options for type 2 diabetes: the old and the new.
    Pratley RE
    Diabetes Educ; 2009; 35 Suppl 1():4S-11S. PubMed ID: 19218561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.
    Suarez-Pinzon WL; Rabinovitch A
    Cell Transplant; 2011; 20(9):1343-9. PubMed ID: 21396168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the science of incretin biology.
    Nauck MA
    Eur J Intern Med; 2009 Jul; 20 Suppl 2():S303-8. PubMed ID: 19580949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling the science of incretin biology.
    Nauck MA
    Am J Med; 2009 Jun; 122(6 Suppl):S3-S10. PubMed ID: 19464426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.